oncolym
mAbexperimentalADC
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2001 (NCT00008021)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
HLA-DRA inhibitor
HLA class II histocompatibility antigen, DRB1-10 beta chain other
Antibody-dependent cell-mediated cytotoxicity (ADCC).
HLA class II histocompatibility antigen, DRB1-10 beta chain other
Antibody-dependent cell-mediated cytotoxicity (ADCC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109447 ↗
Also known as
- lym-1
- lym-1
- oncolym
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00009776 | Phase 1 | Mar 1, 2001 | University of California, Davis |
| NCT00028613 | Phase 1 | Mar 1, 2001 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00008021 | Phase 1 | Feb 1, 2001 | University of California, Davis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Davis | Academic/Hospital | 2 | 2 | 1 | 2001 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2001 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
3 organizations
Page 1 / 1